Omeros ($OMER): The Biotech With No Perfect Peer

This is not the only event that matters, and it may not even be the most durable one. The next quarterly filing will provide the third commercial observation for YARTEMLEA after $9.893 million of first-quarter net sales and $28.529 million in the second quarter. That sequence will help distinguish launch stocking and initial center activation from recurring patient demand. Reimbursement mechanics also improve in stages: permanent HCPCS code J1289 became effective July 1, while the FY2027 New Technology Add-on Payment framework becomes effective October 1 for eligible inpatient cases. Codes and add-on payments reduce friction; they do not guarantee prescriptions, patient starts or recognized revenue.

What the current price appears to require

At $19.33, Omeros’ basic equity value is approximately $1.399 billion using the 72.388 million shares reported outstanding on August 7. A simple enterprise-value bridge starts from June cash and short-term investments of $132.0 million, subtracts the known $60.170 million July repurchase price and $0.223 million of accrued interest, then adds $40.322 million of remaining note principal. The result is roughly $1.368 billion. If the residual notes are instead assumed converted into 6.525 million shares, the indicative enterprise value rises to about $1.454 billion before any incremental option dilution.

Those values equal approximately 11.8–12.6 times the purely mechanical annualization of second-quarter YARTEMLEA sales, $114.116 million. That is not a forecast and not a fair-value conclusion. It is an expectations test: a buyer of the stock is not paying only for a flat continuation of Q2. The price needs some combination of sustained launch growth, attractive long-term margins, European or new-indication value, cash milestones and royalties from Novo, or value from the retained pipeline. If several of those fail together, the multiple has little operating protection.

What YARTEMLEA has to prove commercially

Hospital launches are different from retail chronic-drug launches. TA-TMA diagnosis is complex, patients are acutely ill, treatment decisions are concentrated among transplant centers and reimbursement flows through institutions. A code can simplify billing, and NTAP can improve hospital economics, but neither is patient demand. The variables that matter are the number of activated centers, time from diagnosis to treatment, first-line versus rescue use, repeat ordering, average doses per patient, discontinuation patterns, gross-to-net evolution and whether the drug is used across adult and pediatric populations consistent with the label.

The label’s dosing also matters to revenue quality. Patients weighing at least 50 kilograms receive 370 mg intravenously once weekly over 30 minutes, with the possibility of increasing to twice weekly if clinical response is inadequate. Those below 50 kilograms receive 4 mg/kg. Duration therefore depends on clinical course. Revenue can rise because more patients are treated, because treatment lasts longer, or because intensity increases. Only the first is unambiguously a breadth-of-adoption signal. The filings do not yet provide enough patient-level detail to separate these effects.

Why the Novo transaction helps, but cannot be booked twice

In December 2025 Omeros closed the sale and license of zaltenibart, formerly OMS906, to Novo Nordisk. Omeros received $240 million upfront and became eligible for up to $510 million in development and regulatory milestones, including $100 million that management described as potentially achievable in the near term, plus up to $1.3 billion in commercial milestones and high-single-digit to high-teens royalties on net sales. Novo obtained global rights and controls development. Omeros retained certain MASP-3 small-molecule and grandfathered antibody rights, subject to contractual restrictions.

The transaction lowered direct development burden and supplied non-dilutive capital. It also transferred control of the most advanced MASP-3 asset. A proper valuation therefore uses a probability-weighted present value of each remaining milestone and royalty stream; it does not add $1.81 billion of contingent payments to market capitalization. It also avoids counting the $240 million upfront as future value after that cash has already financed debt repayment, note repurchases and operations.

What is plausibly mispriced

• Potentially underappreciated: the first approved drug in TA-TMA can shape the treatment pathway, and two sequential launch quarters show genuine commercial traction rather than zero-revenue optionality.
• Potentially overappreciated: Q2 growth may contain launch effects; early cost of sales is artificially low; European approval is unresolved; and the market pays a premium to a static sales denominator.
• Hard to value: Novo milestones, OMS1029 indication selection, investigator-sponsored studies and preclinical programs can create large outcomes but have insufficient timing or probability detail for a defensible target today.
• Often misunderstood: OMIDRIA royalty receivables are linked to a royalty-funding obligation. The gross asset is not free cash available to fund YARTEMLEA.

The pivotal evidence package

The central clinical study was a prospective, open-label, single-arm trial in 28 adults with HSCT-TMA. Patients received intravenous narsoplimab once weekly for four to eight weeks. The primary response endpoint required improvement in both laboratory TMA markers and either organ function or transfusion status. Seventeen of 28 patients, or 61%, met the composite response definition. The Journal of Clinical Oncology paper reported 68% survival at 100 days after TA-TMA diagnosis for the full analysis set and 94% among responders.

These numbers are clinically encouraging in a severe condition, but the design limits causal interpretation. There was no randomized concurrent control, the sample was small, patient management can vary across transplant centers, and responder survival is a post-baseline subgroup that benefits from selection. The FDA nevertheless judged the total evidence sufficient for approval, using the pivotal study plus expanded-access evidence, pharmacology, safety and the unmet need. Investors should respect both facts at once: the drug is fully FDA approved for the labeled population, and the comparative magnitude of benefit remains less certain than it would be after a randomized trial.

Real-world data are directionally consistent. A 20-patient compassionate-use cohort published by Castelli and colleagues reported a 65% response rate and 70% survival 100 days after diagnosis. A larger expanded-access analysis included 136 adults and children and reported one-year survival stratified by age, risk and line of therapy. These studies broaden the experience but do not solve the control problem: treatment selection, missing data, changes in supportive care and sponsor involvement can influence observed results.

Safety must be read in the context of an extremely ill population

In the 28-adult safety dataset, the FDA label reports serious adverse reactions in 61%, serious infections in 36% and fatal adverse reactions in 7%. The most common adverse reactions included infections, gastrointestinal disorders, respiratory events, edema and hypertension. These patients are medically fragile and the label tabulates adverse events regardless of causality; the numbers should not be presented as though YARTEMLEA caused every event. The opposite spin is also wrong: absence of a boxed warning or REMS does not mean an absence of serious infection risk. The expanded-access safety population included 221 adults and children, with a median of eight doses over 5.5 weeks, and the label states that no new significant safety signals were identified.

How to think about C5 inhibition

Eculizumab has been used off label in TA-TMA. A systematic review and meta-analysis of 116 patients across six mainly observational studies estimated a 71% overall response rate, 32% complete response rate and 52% survival at the last follow-up, with substantial heterogeneity. A 2025 Mayo Clinic series of 99 adult TA-TMA cases reported a 6.2% incidence after allogeneic transplant and highlighted infection, graft-versus-host disease and organ dysfunction as high-risk features. Eleven patients received eculizumab, with an observed 70% response rate, but the subgroup was far too small and non-randomized for a cross-drug conclusion.

AstraZeneca separately reported that the adult/adolescent Phase 3 trial of ravulizumab in HSCT-TMA did not meet its primary endpoint, while a pediatric study produced a survival result. That failed trial underscores how difficult TA-TMA development is. It does not validate narsoplimab, and it does not establish head-to-head superiority. Different populations, endpoints, timing and supportive care make naïve comparisons unreliable.

Catalyst map: confirmed facts versus inferred windows

Evidence grade

For the approved U.S. indication, regulatory certainty is high and comparative certainty is moderate-to-low. For commercial adoption, evidence is early but measurable. For European approval, the status is explicitly adverse and unresolved. For OMS1029 and the oral MASP-2 program, mechanism and early pharmacology exist but human efficacy does not. For Novo economics, the contract exists but the future cash flows are probabilistic and externally controlled.

Why GAAP net income is misleading for valuation

Omeros reported $69.292 million of net income for the first half of 2026. That figure included an $84.593 million non-cash gain from changes in the fair value of financial liabilities. It does not represent recurring operating profitability and makes a P/E ratio meaningless. The more informative indicators are product revenue, normalized gross margin, operating expenses, operating cash flow and the number of quarters the current capital can support under different launch paths.

First-half operating cash use was $10.357 million, while Q2 alone generated approximately $4.1 million of operating cash. The improvement is important, but runway cannot be expressed as “cash divided by last-quarter burn” because the denominator changed sign during a launch and the numerator changed materially after quarter end. A responsible runway view needs a pro-forma cash balance, normalized inventory costs, launch investment and scenarios for receivables and stocking.

OMIDRIA: asset and obligation belong in the same sentence

The June balance sheet included current and non-current OMIDRIA royalty-related assets of roughly $116.5 million and current and non-current royalty obligations totaling about $157.9 million. Omeros sold rights to certain U.S. royalties through 2031 to DRI Healthcare. Legal waterfalls, timing, discount rates and foreign economics matter. It is therefore wrong to add the gross royalty asset to cash or to subtract the entire obligation as ordinary debt without reconstructing the contract. In this preliminary report the arrangement is treated as a separate structured claim, not as free liquidity.

The answer is a peer stack, not a peer ticker. Each group answers a different question. Zevra is the closest near-term commercial benchmark because it also launched a first-in-disease rare-disease product and reported a very similar quarterly product-sales number. Annexon and Dianthus test how public markets value complement platforms before commercial revenue. BioCryst and Travere show what larger rare-disease franchises look like after adoption is established. InflaRx is a reminder that complement biology alone does not guarantee a valuation premium. Recent transactions show strategic appetite, but control premiums and synergies make them unsuitable as direct trading multiples.

The superficial multiple screen

Using equity value divided by the latest quarter’s product sales annualized—a deliberately crude screen—OMER is about 12.3 times, ZVRA about 6.0 times on MIPLYFFA alone, BCRX about 4.1 times total product sales and TVTX about 11.1 times FILSPARI sales. These are not comparable enterprise-value multiples: cash, debt, other revenue, growth rates, tax assets, royalties and pipelines differ. The screen has one legitimate use: it shows that Omeros already trades closer to a premium-growth commercial reference than to the closest launch-stage sales peer.

Why might that be justified? TA-TMA has no other FDA-approved treatment; Q2 growth was sharp; hospital reimbursement is improving; the product could expand geographically or into additional research settings; and Omeros retains milestones, royalties and pipeline options. Why might it be dangerous? Q2 is only the second commercial quarter, comparative efficacy is uncertain, Europe is adverse, post-July cash is much lower than the headline June number, and options can add material shares.

Transaction precedents: useful ceilings, bad direct multiples

Chiesi completed its acquisition of KalVista after an announced fully diluted value of approximately $1.9 billion at $27 per share. Biogen’s acquisition accounting for Apellis recorded consideration of roughly $5.41 billion. These deals prove that strategic buyers pay for rare-disease franchises and complement assets. They do not mean OMER is worth the same. KalVista and Apellis had different products, patent lives, cash positions, competitive sets, revenue trajectories and synergy value. Control transactions also embed a premium unavailable to a minority public shareholder unless an acquisition occurs.

A valuation bridge instead of a false price target

At the current price, the enterprise-value bridge exceeds the Q2 annualized product-sales denominator by roughly $1.24–$1.32 billion. That residual is not “overvaluation” by definition. It is the amount that must be justified by launch growth, duration, margins and optionality after accounting for risk. The research task is therefore not to find one peer with the same market cap. It is to test whether the residual claim has enough probability-weighted value.

These scenarios are operating states, not target prices. The sales bands are deliberately broad and should be replaced by a patient-based model before a formal valuation. Their purpose is to show which facts would change the thesis.

Proof points and kill criteria

What would change our mind?

A higher price alone would not make the thesis better, and a lower price alone would not repair weak launch evidence. The report would become more constructive if Omeros disclosed patient and center metrics that demonstrate broadening adoption, if post-inventory gross margin remained compelling, and if Europe or OMS1029 moved from vague option to dated, testable program. It would become more cautious if Q2 proved to be a transient launch high, if cash fell faster than the operating model suggests, or if management used the ATM before clarifying the return on that capital.

Management’s highest-return task is not to maximize the number of pipeline programs. It is to convert the first approved TA-TMA label into a durable hospital franchise while preserving enough capital to fund the programs that can actually change value. The Novo transaction reduces MASP-3 spending and provides contingent upside, but it also means Omeros no longer controls the timing of that asset. Retained programs should be judged against the alternative of strengthening the launch or avoiding dilution.

1. Make commercial quality visible. Report activated centers, new versus repeat orders, treatment duration, net price and reimbursement time where competitively possible.
2. Resolve the European branch. A favorable re-examination would create a partner-or-build decision. A sustained negative opinion should trigger a transparent evidence and resubmission plan, not euphemistic language.
3. Select OMS1029’s indication with discipline. Quarterly IV/subcutaneous pharmacology is not an investment thesis until linked to a disease, trial design, endpoint and budget.
4. Protect the balance sheet. Use the ATM only when the expected value of the funded activity exceeds dilution, and report the pro-forma share count clearly.
5. Treat Novo milestones as external options. Communicate only milestones whose triggering conditions and timing can be responsibly described.
6. Use investigator-sponsored studies as learning options. ARDS and prophylactic TA-TMA work can generate signals, but they should not be capitalized as approved-market extensions.

No Reddit, Stocktwits or X score is presented because a reproducible, time-stamped sample was not archived for this edition. Omitting a weak sentiment number is more informative than presenting an unauditable one. Social discussion can identify questions, but it cannot verify regulatory status, clinical benefit or capital structure.

Omeros has crossed the most important line in biotech: YARTEMLEA is FDA approved, commercially available and generating material revenue. The clinical signal is supported by an approved label, a 28-patient pivotal study and consistent observational experience, but there is no randomized head-to-head basis for superiority claims. The European path is unresolved after a negative CHMP opinion. The balance sheet is stronger than before the Novo transaction, yet the June cash headline overstates post-July liquidity and the option/convertible stack matters.

The best operational peer is Zevra; the best scientific peers are Annexon and Dianthus; the best maturity checks are BioCryst and Travere; InflaRx is the useful negative control. None is sufficiently similar to justify a one-step multiple. A defensible value must build YARTEMLEA from patients and centers, risk-adjust Europe and Novo cash flows, assign conservative value to early pipeline assets, then reconcile cash, notes, options, ATM capacity and OMIDRIA claims.

Merlintrader stance: researched watchlist / preliminary initiation. The company is no longer a binary development story, but the current price already assumes meaningful success beyond the static Q2 run rate. The next upgrade in conviction should come from commercial-quality disclosure and a patient-based model—not from a higher share price, a transaction headline or an analyst target scraped from an aggregator.

• Omeros Corporation ($OMER) Stock Hub
• Biotech Stocks Hub and 2026 Catalysts

For a broader, continuously updated view of biotech events, use the Merlintrader Biotech Catalyst Calendar.

Editorial cutoff: August 27, 2026. Published on Merlintrader and contains no personalized recommendation.